Recombinant Virus Production
Recombinant Virus Production - Related Videos
04:12
Production and Purification of Recombinant Hepatitis B Virus Particles
0 Views •
2026
Source: Nishitsuji, H., et al. Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle. J. Vis. Exp. (2017)This video demonstrates the production and purification of recombinant Hepatitis B virus particles, enabling safe, replication-deficient viral preparations for studying early infection events and for high-throughput antiviral drug screening applications.
03:11
Polyethylenimine-Mediated Transfection of Embryonic Kidney Cells for Recombinant Virus Production
0 Views •
2026
Source: Van Lidth de Jeude, et al. A Protocol for Lentiviral Transduction and Downstream Analysis of Intestinal Organoids. J. Vis. Exp. (2015).This video demonstrates the process of producing viral particles through transfection of embryonic kidney cells with plasmid–polyethylenimine complexes, which leads to viral genome expression, particle assembly, and virus collection in the medium.
13:47
Efficient Recombinant Parvovirus Production with the Help of Adenovirus-derived Systems
0 Views •
Cited by 8 •
2012
Here we describe a protocol based only on cell infection, which improves the efficiency of recombinant parvovirus production by more than 100 fold in comparison to other protocols in use. This protocol relies on the use of a novel adenovirus 5-based helper containing the parvovirus VP transcription unit (Ad-VP).
02:58
Generating Recombinant Live-Attenuated Influenza Viruses for Vaccines
0 Views •
2025
The video showcases a method to create cold-adapted recombinant influenza viruses. It involves transfecting human cells with bi-directional plasmids, followed by incubation at lower temperature incubation to yield viruses suitable for vaccine production, characterized by reduced replication in warmer conditions.
11:31
Generation of Recombinant Influenza Virus from Plasmid DNA
0 Views •
Cited by 129 •
2010
Rescue of influenza A viruses from plasmid DNA is a basic and essential experimental technique that allows influenza researchers to generate recombinant viruses to study multiple aspects in the biology of influenza virus, and to be used as potential vectors or vaccines.
FAQs
The inserted sequence determines the genetic payload carried by the viral vector and therefore what the resulting particles can deliver. In immunology, selecting an antigen-encoding sequence can support controlled antigen delivery, whereas other payloads can support gene-delivery studies. Payload design therefore links genome engineering to the intended experimental readout, such as an immune response or delivery outcome.
Permissive producer cells provide the cellular environment required for engineered viral genomes to generate particles. Their role connects genome introduction with particle assembly and release, so the production system must be maintained under controlled conditions. If that cellular step is not effective, downstream measurements of yield, payload, and activity cannot accurately represent the intended preparation.
Particle yield alone does not establish that a preparation is suitable. Researchers also examine whether the intended genetic payload is present and whether the particles show the expected functional activity. Considering these measures together distinguishes quantity from biological performance and provides a more informative basis for deciding whether material is ready for research use.
Controlled conditions matter because the process depends on both the engineered genome and the producer-cell environment. Researchers need permissive cells and conditions that allow cellular machinery to assemble and release particles. Maintaining those requirements helps preserve the connection between the intended construct and measurable outputs, including particle yield, payload representation, and functional activity.
Postproduction assessment should address four complementary properties: particle yield, the presence of the intended genetic payload, functional activity, and biosafety. Yield indicates how much material was generated, while payload and activity address whether it represents a functional version of the intended construct. Biosafety assessment determines whether the preparation is appropriate for its planned use.
Viral particles carrying selected antigen sequences can deliver antigens and enable measurement of resulting immune responses. This makes the approach useful for evaluating vaccine concepts, because researchers can connect a defined genetic payload with immunological readouts. It also places antigen delivery and response measurement within a controlled experimental system relevant to immunology and infection research.
The system can provide a way to deliver selected genetic sequences while researchers model host-pathogen interactions. By linking a defined viral payload with functional activity measurements and immune-response analysis, experiments can examine how engineered particles perform in an infection-related context. This complements vaccine studies and extends use toward broader gene-delivery and infection research.